Patent ID: 9671405
Date: 2017-06-06
CPC Classifications: A61K,C12Q,G01N

Claim:
1. A method of treating a prostate cancer patient comprising: quantifying expression of androgen receptor splice variant v5,6,7, with at least 95% sequence identity to SEQ ID NO:3, in a test sample obtained from the patient; quantifying expression of androgen receptor splice variant v7 with at least 95% sequence identity to SEQ ID NO:5 in the test sample; and administering a taxane if the quantity of androgen receptor v5,6,7 splice variant is greater than the quantity of androgen receptor splice variant v7 the test sample; but not administering a taxane if more androgen receptor splice variant v7 with at least 95% sequence identity to SEQ ID NO:5 is present in a test sample than variant v5,6,7.